Setiptiline


Setiptiline, also known as teciptiline, is a tetracyclic antidepressant which acts as a noradrenergic and specific serotonergic antidepressant. It was launched in 1989 for the treatment of depression in Japan by Mochida.

Pharmacology

Pharmacodynamics

Setiptiline acts as a norepinephrine reuptake inhibitor, α2-adrenergic receptor antagonist, and serotonin receptor antagonist, likely at the 5-HT2 subtypes, as well as an H1 receptor inverse agonist/antihistamine.

Chemistry

Setiptiline has a tetracyclic structure and is a close analogue of mianserin and mirtazapine, with setiptiline being delta,4a-carba-mianserin, and mirtazapine being 6-azamianserin.